Cargando…

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

Detalles Bibliográficos
Autores principales:	Váraljai, Renáta, Zimmer, Lisa, Al-Matary, Yahya, Kaptein, Paulien, Albrecht, Lea J., Shannan, Batool, Brase, Jan C., Gusenleitner, Daniel, Amaral, Teresa, Wyss, Nina, Utikal, Jochen, Flatz, Lukas, Rambow, Florian, Reinhardt, Hans Christian, Dick, Jenny, Engel, Daniel R., Horn, Susanne, Ugurel, Selma, Sondermann, Wiebke, Livingstone, Elisabeth, Sucker, Antje, Paschen, Annette, Zhao, Fang, Placke, Jan M., Klose, Jasmin M., Fendler, Wolfgang P., Thommen, Daniela S., Helfrich, Iris, Schadendorf, Dirk, Roesch, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518252/ https://www.ncbi.nlm.nih.gov/pubmed/37580519 http://dx.doi.org/10.1038/s43018-023-00632-w

Ejemplares similares

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype
por: Albrecht, Lea Jessica, et al.
Publicado: (2022)

COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates
por: Lodde, Georg C., et al.
Publicado: (2022)

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
por: Cosgarea, Ioana, et al.
Publicado: (2017)

Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival
por: Thielmann, Carl Maximilian, et al.
Publicado: (2022)

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
por: Brase, Jan C., et al.
Publicado: (2021)

Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma
por: Váraljai, Renáta, et al.
Publicado: (2021)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study
por: Lodde, Georg Christian, et al.
Publicado: (2023)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
por: Placke, Jan-Malte, et al.
Publicado: (2023)

Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study
por: Placke, Jan-Malte, et al.
Publicado: (2021)

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients
por: Schrama, David, et al.
Publicado: (2014)

Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
por: Matull, Johanna, et al.
Publicado: (2020)

The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling
por: Stockmann, Christian, et al.
Publicado: (2014)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis
por: Sondermann, Wiebke, et al.
Publicado: (2016)

Analysis of SDHD promoter mutations in various types of melanoma
por: Scholz, Simone L., et al.
Publicado: (2015)

The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition
por: Hegedüs, Luca, et al.
Publicado: (2022)

Kutanes Angiosarkom mit klinischem Bild eines Quincke-Ödems
por: Albrecht, M., et al.
Publicado: (2021)

B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
por: Ugurel, Selma, et al.
Publicado: (2007)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
por: Zaremba, Anne, et al.
Publicado: (2019)

Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions
por: Zaremba, Anne, et al.
Publicado: (2022)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

Multimodal predictors for precision immunotherapy
por: Roelofsen, L.M., et al.
Publicado: (2022)

Externe wissenschaftliche Evaluation der ersten Teledermatologie-App ohne direkten Patientenkontakt in Deutschland („Online Hautarzt – AppDoc“)
por: Sondermann, Wiebke, et al.
Publicado: (2020)

Lack of clinical efficacy of imatinib in metastatic melanoma
por: Ugurel, S, et al.
Publicado: (2005)

Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
por: Martins Nascentes Melo, Luiza, et al.
Publicado: (2023)

Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
por: Thier, Beatrice, et al.
Publicado: (2022)

SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma
por: Willmes, Christoph, et al.
Publicado: (2016)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Persister state-directed transitioning and vulnerability in melanoma
por: Chauvistré, Heike, et al.
Publicado: (2022)

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
por: Tawbi, Hussein A, et al.
Publicado: (2022)

Dose-dependent severe cutaneous reactions to imatinib
por: Ugurel, S, et al.
Publicado: (2003)

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
por: Sucker, Antje, et al.
Publicado: (2017)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
por: Sondermann, Wiebke, et al.
Publicado: (2015)

Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
por: Franklin, Cindy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0feonj7vruu3bhoeiisalaufln